Dr.Reddy's Laboratories Ltd (REDY.NS)
23 Feb 2017
* Says the audit of API manufacturing plant at Miryalaguda, by the US FDA, has been completed on February 21, 2017
* Clarifies on news item "Dr. Reddy's announces US district court's opinion relating to patent infringement"
** Shares of Dr Reddy's Laboratories fall as much as 3.9 pct, their lowest since Jan 22, 2016
* Says Dr. Reddy's Laboratories announces U.S. district court's opinion relating to patent infringement
* Dr.Reddy's Laboratories clarifies on news item "Korean biotech firm Mezzion Pharma files suit against Dr Reddy's laboratories."
- Note: Reuters has not verified this story and does not vouch for its accuracy
* Clarifies on news item "FDA to re-audit three Dr.Reddy's labs plants"
* Announces the launch of Raloxifene HCI tablets, USP in the U.S. Market Source text: http://bit.ly/2fHr5V4 Further company coverage:
* Sucampo pharmaceuticals inc - company raises 2016 guidance and provides preliminary 2017 guidance
** Shares of India's drugmakers fall, sending Nifty Pharma index down as much as 4.5 pct to lowest since June 24